EPEMED the European Personalised Medicine association appoints its General Delegate and several new board members
EPEMED has appointed Mrs Emmanuelle Benzimra as new General Delegate of the association based in Luxembourg.
Emmanuelle Benzimra has a broad experience in various sectors including the finance and investment banking industry, non-profit start-ups and philanthropic organisations to which she brings her dynamism, expertise and skills in business development and management.
Furthermore, 3 new board members are appointed : Patrizia Luchetta, Werner Verbiest and Peter Collins.
Patrizia Luchetta is the Director of New Technologies at Ministry of the Economy and of Foreign Trade, Grand Duchy of Luxembourg. She has been the lead agent in developing the Health Sciences and Technologies Hub, to bring expanded research, business and job opportunities to the Luxembourg economy. Patrizia sits on the Board of the Integrated Biobank of Luxembourg (IBBL) as deputy chairman, and on the Board of Integrated Diagnostics, a Seattle-based start-up.
Werner Verbiest is Global Head of Janssen Diagnostics. In this capacity, Werner plays a leading role in advocating for and actualizing a personalised medicine approach within Johnson & Johnson/Janssen and carries an extensive track record in drug development projects, clinical trials, product marketing and executive management acquired at leading pharmaceutical firms.
Peter Collins is Vice President, Head of Diagnostics at GSK. Peter leads GSK's Diagnostic Nucleus focused on supporting the diagnostic needs of GSK's Clinical Development Programs across all business units. Peter has over 30 year experience in the Diagnostics industry, specializing in Companion Diagnostics and Personalised Medicine, an area for which he has a real passion and commitment to see delivered.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.